BIOCON Biocon Q1 FY27 results (Apr–Jun 2026) and concall
Biocon Limited reported a strong Q1 FY27, with group operating revenue growing 10% YoY and biopharmaceuticals leading the charge with 17% growth. Net profit before exceptionals soared 245% YoY, supported by improved generics profitability and reduced interest costs. While the services segment faced headwinds with a 16% revenue decline, management expressed confidence in a progressive build-up of momentum through the year, particularly in biosimilars, with new launches and expanded manufacturing capabilities driving future growth.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q1 FY27: revenue up 10.0%, net profit up 53.9% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 3,590 | 3,821 | 4,417 | 3,942 | 4,296 +20% | 4,173 +9% | 4,517 +2% | 4,336 +10% |
| EBITDA | 685 | 752 | 1,078 | 766 | 835 +22% | 834 +11% | 1,020 −5% | 847 +11% |
| Net profit | 27 | 81 | 459 | 89 | 133 +393% | -52 −164% | 199 −57% | 137 +54% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
